The eye in sleep apnea syndrome.
Sleep apnea syndrome (SAS) is a disease characterized by recurrent complete or partial upper airway obstructions during sleep. The majority of patients with SAS demonstrate this obstruction either at the nasopharynx or the oropharynx. Risk factors for SAS include obesity, male gender, upper airway abnormalities, alcohol use, snoring, and neck girth of more than 17 in. in men or 16 in. in women. Reported ophthalmic findings in patients with SAS include floppy eyelid syndrome (FES), glaucoma, and non-arteritic anterior ischemic optic neuropathy (NAION).
Abdal
Helen
H
Health Professions Division, College of Optometry, Nova Southeastern University, 3200 South University Drive, Ft. Lauderdale, FL 33328-2018, USA.
Pizzimenti
Joseph J
JJ
Purvis
Cheryl C
CC
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D045422:Continuous Positive Airway Pressure / Q000379:methods; D004549:Elastin / Q000378:metabolism; D004917:Erythromycin / Q000627:therapeutic use; D005123:Eye / Q000503:physiopathology*; D005141:Eyelid Diseases / Q000188:drug therapy / Q000453:epidemiology* / Q000503:physiopathology*; D005901:Glaucoma / Q000175:diagnosis / Q000453:epidemiology* / Q000503:physiopathology; D006801:Humans; D008382:Marfan Syndrome / Q000175:diagnosis / Q000453:epidemiology* / Q000503:physiopathology; D009900:Optic Nerve / Q000503:physiopathology; D018917:Optic Neuropathy, Ischemic / Q000175:diagnosis / Q000453:epidemiology* / Q000503:physiopathology; D020181:Sleep Apnea, Obstructive / Q000453:epidemiology* / Q000503:physiopathology* / Q000628:therapy
D000900:Anti-Bacterial Agents; D004917:Erythromycin; D004549:Elastin